This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Wednesday's Health Winners & Losers

Then Applera's (ABI) Celera Group (CRA) reported net income of $700,000, or one cent a share, for the first quarter of 2008, compared with a net loss of $7.1 million, or 9 cents a share, in the year-ago period that included a pretax charge of $3.5 million. Revenue increased by 58% to $16.1 million from $10.2 million. Celera predicts revenue between $135 million and $145 million for its fiscal 2008.

Separately, Celera said after Tuesday's close that it has completed the acquisition of substantially all of the assets of Atria Genetics for roughly $33 million in cash. It anticipates the acquisition will be accretive by the second half of its fiscal 2008.

Celera shares fell 55 cents, or 3.5%, to $15. Applera was up a slight 0.3% at $35.34.

One winner, Genzyme (GENZ) beat estimates. Excluding items, the company reported earning $241.3 million, or 90 cents a share, compared to $195.9 million, or 73 cents a share, in the comparable 2006 period. Revenue climbed 19% to $960.2 million from $808.6 million in the year-ago period. The Thomson Financial consensus target was 87 cents a share on revenue of $954 million. Genzyme shares rose $2.24, or 3.1%, to $75.75.

Meanwhile, away from earnings, Oncolytics Biotech (ONCY) said Wednesday that it received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to begin a clinical trial using IV-administered Reolysin with cyclophosphamide (a chemtherapeutic agent and immune modulator) in patients with advanced cancers. Shares gained 19 cents, or 8.2%, to $2.52.

Also up, Cephalon (CEPH) announced Tuesday after close that a phase III trial of Treanda in patients with indolent non-Hodkin's lymphoma (NHL) met its primary endpoints of overall response rate and median duration of response. The company said that Treanda also had a manageable tolerability profile in the study, which was conducted on patients whose cancer was no longer responsive to treatment with rituximab. Cephalon's shares rose $2.97, or 4.2%, to $74.05.

2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs